Cargando…
Immunotherapy for Parkinson’s disease
With the increasing prevalence of Parkinson’s disease (PD), there is an immediate need to interdict disease signs and symptoms. In recent years this need was met through therapeutic approaches focused on regenerative stem cell replacement and alpha-synuclein clearance. However, neither have shown lo...
Autores principales: | Schwab, Aaron D., Thurston, Mackenzie J., Machhi, Jatin, Olson, Katherine E., Namminga, Krista L., Gendelman, Howard E., Mosley, R. Lee |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7933730/ https://www.ncbi.nlm.nih.gov/pubmed/31978602 http://dx.doi.org/10.1016/j.nbd.2020.104760 |
Ejemplares similares
-
A Synthetic Agonist to Vasoactive Intestinal Peptide Receptor-2 Induces Regulatory T Cell Neuroprotective Activities in Models of Parkinson’s Disease
por: Mosley, R. Lee, et al.
Publicado: (2019) -
Safety, tolerability, and immune-biomarker profiling for year-long sargramostim treatment of Parkinson's disease
por: Olson, Katherine E., et al.
Publicado: (2021) -
Interleukin-2 expands neuroprotective regulatory T cells in Parkinson’s disease
por: Markovic, Milica, et al.
Publicado: (2022) -
Monocyte biomarkers define sargramostim treatment outcomes for Parkinson's disease
por: Abdelmoaty, Mai M., et al.
Publicado: (2022) -
An open-label multiyear study of sargramostim-treated Parkinson’s disease patients examining drug safety, tolerability, and immune biomarkers from limited case numbers
por: Olson, Katherine E., et al.
Publicado: (2023)